| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 9 | — | 17.8x | Bottom tier | |
Growth | 10 | -28.6% | 7.1% | Bottom tier | |
Quality | 40 | -32.3% | 4.5% | Around median | |
Safety | 36 | — | 2.6x | Bottom tier | |
Capital Return | 87 | — | 2.12% | Top tier | |
Momentum | 95 | 165.2% | 2.9% | Top tier | |
Sentiment | 49 | 11 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Xencor, Inc. is a biopharmaceutical company developing engineered antibodies, with its business centered on the XmAb platform and bispecific programs designed to activate T cells against solid tumors. Its internal portfolio includes vudalimab, XmAb819, XmAb808, and XmAb541, while partnerships, licensing, and royalties contribute to revenue; management described these sources as playing an important role in 2023, citing collaborations with Amgen and J&J and royalties from Ultomiris and Monjuvi. The company's model therefore depends on the progress of its internal clinical assets and on milestone payments and royalties associated with licensed programs, rather than on a single internally developed commercial product mentioned in the provided data.
In fiscal Q1 2026, Xencor reported revenue of $4.5 million and a net loss of $128.9 million, equivalent to a loss of $1.71 per share. These figures compare with revenue of $28.2 million and a net loss of $6.7 million in fiscal Q4 2025, highlighting substantial volatility between periods, while fiscal 2025 revenue was approximately $125.6 million and the net loss was $91.9 million. On a trailing twelve-month basis in 2026, revenue was $97.4 million, the net loss was $172.4 million, and earnings per share were negative $2.2914.
Automated analysis for informational purposes only — not investment advice.
No usable price-to-earnings ratio is available because of the losses, while the stock's 52-week range extends from $7.91 to $30.61. The average analyst target is $30.33, very close to the upper end of that range, with a wide dispersion between $20 and $44 and a consensus rating of “Buy”; this divergence reflects uncertainty about converting clinical data into economic value amid a trailing twelve-month net loss of $172.4 million in 2026.
Figures in the text are as of 2026-09-01; the live price is shown at the top of the page.
Xencor relies on partnerships, licensing, and royalties associated with the XmAb platform and antibody programs, and management described these sources as playing an important role in 2023. Examples included the XmAb 2+1 CD3 collaboration with Amgen, CD28 bispecific programs with J&J, and royalties from Ultomiris and Monjuvi. Revenue totaled $125.6 million in fiscal 2025, but fell to $4.5 million in fiscal Q1 2026, illustrating the volatility of this model between periods.
In the presentation dated February 28, 2024, vudalimab monotherapy achieved a RECIST response rate of 35% and a disease control rate of 50% among patients with metastatic castration-resistant prostate cancer. The PSA90 rate was approximately 25%, and one patient had stable disease for more than 48 weeks. Patients had received a median of four prior therapies, and management said expanding the cohort to approximately 20 or 30 patients was necessary to assess the durability of the signal.
XmAb819, a bispecific antibody targeting ENPP3 and CD3, was undergoing dose escalation in phase 1 for renal cell carcinoma, according to the February 28, 2024 call. XmAb808, targeting B7-H3 and CD28, was advancing in a phase 1 study in combination with pembrolizumab. The company also identified CLDN6-targeted XmAb541 as a program for tumors including ovarian cancer, while its partner Amgen's Xaluritamig provided early clinical validation of the XmAb 2+1 CD3 design.
The net loss totaled $128.9 million in fiscal Q1 2026 against revenue of $4.5 million, and the loss per share was $1.71. On a trailing twelve-month basis in 2026, the net loss reached $172.4 million, so no valid price-to-earnings ratio is available for comparison. Clinically, one case of grade 5 immune-mediated hepatitis was reported among more than 240 patients who had received vudalimab as of February 28, 2024, and most of the programs mentioned were in early stages.
The analyst consensus is rated “Buy,” with an average price target of $30.33. The target range extends from $20 to $44, a wide dispersion reflecting differing expectations regarding the clinical portfolio's chances of success. The average is near the upper end of the 52-week range of $30.61, but the absence of profits and the widening net loss in fiscal Q1 2026 make the valuation primarily dependent on trial results and partnerships.
